250 related articles for article (PubMed ID: 16420986)
21. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.
Wolanskyj AP; Lasho TL; Schwager SM; McClure RF; Wadleigh M; Lee SJ; Gilliland DG; Tefferi A
Br J Haematol; 2005 Oct; 131(2):208-13. PubMed ID: 16197451
[TBL] [Abstract][Full Text] [Related]
22. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
Scott LM; Tong W; Levine RL; Scott MA; Beer PA; Stratton MR; Futreal PA; Erber WN; McMullin MF; Harrison CN; Warren AJ; Gilliland DG; Lodish HF; Green AR
N Engl J Med; 2007 Feb; 356(5):459-68. PubMed ID: 17267906
[TBL] [Abstract][Full Text] [Related]
23. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
24. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects.
James C; Ugo V; Casadevall N; Constantinescu SN; Vainchenker W
Trends Mol Med; 2005 Dec; 11(12):546-54. PubMed ID: 16271512
[TBL] [Abstract][Full Text] [Related]
25. The incidence of the JAK2 V617F mutation in patients with idiopathic erythrocytosis.
Percy MJ; Jones FG; Green AR; Reilly JT; McMullin MF
Haematologica; 2006 Mar; 91(3):413-4. PubMed ID: 16503548
[TBL] [Abstract][Full Text] [Related]
26. The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera.
Cario H; Goerttler PS; Steimle C; Levine RL; Pahl HL
Br J Haematol; 2005 Sep; 130(5):800-1. PubMed ID: 16115144
[No Abstract] [Full Text] [Related]
27. Case 15-2006: the Budd-Chiari syndrome and V617F mutation in JAK2.
Spivak JL; Moliterno AR; Silver RT
N Engl J Med; 2006 Aug; 355(7):737; author reply 738. PubMed ID: 16914715
[No Abstract] [Full Text] [Related]
28. [Myeloproliferative diseases caused by JAK2 mutation].
Nagata K; Shimoda K
Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
[TBL] [Abstract][Full Text] [Related]
29. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
30. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
31. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
32. JAK2 mutations in myeloproliferative disorders.
Tefferi A; Lasho TL; Gilliland G
N Engl J Med; 2005 Sep; 353(13):1416-7; author reply 1416-7. PubMed ID: 16192494
[No Abstract] [Full Text] [Related]
33. Methods for the detection of the JAK2 V617F mutation in human myeloproliferative disorders.
Campbell PJ; Scott LM; Baxter EJ; Bench AJ; Green AR; Erber WN
Methods Mol Med; 2006; 125():253-64. PubMed ID: 16502590
[TBL] [Abstract][Full Text] [Related]
34. [Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection].
Andrikovics H; Szilvási A; Meggyesi N; Király V; Halm G; Lueff S; Nahajevszky S; Mikala G; Sipos A; Lovas N; Csukly Z; Mátrai Z; Tamáska J; Tordai A; Masszi T
Orv Hetil; 2007 Feb; 148(5):203-10. PubMed ID: 17344140
[TBL] [Abstract][Full Text] [Related]
35. The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis.
Tefferi A; Gilliland DG
Mayo Clin Proc; 2005 Jul; 80(7):947-58. PubMed ID: 16007902
[TBL] [Abstract][Full Text] [Related]
36. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis.
James C; Delhommeau F; Marzac C; Teyssandier I; Couédic JP; Giraudier S; Roy L; Saulnier P; Lacroix L; Maury S; Tulliez M; Vainchenker W; Ugo V; Casadevall N
Leukemia; 2006 Feb; 20(2):350-3. PubMed ID: 16341032
[No Abstract] [Full Text] [Related]
37. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
Hussein K; Bock O; Kreipe H
Pathobiology; 2007; 74(2):72-80. PubMed ID: 17587878
[TBL] [Abstract][Full Text] [Related]
38. The JAK2 V617F mutation is absent in patients with erythrocytosis due to high oxygen affinity hemoglobin variants.
McClure RF; Hoyer JD; Mai M
Hemoglobin; 2006; 30(4):487-9. PubMed ID: 16987804
[TBL] [Abstract][Full Text] [Related]
39. No evidence for JAK2(V617F) mutation in monoclonal B cells in 2 patients with polycythaemia vera and concurrent monoclonal B cell disorder.
Stijnis C; Kroes WG; Balkassmi S; Marijt EW; van Rossum AP; Bakker E; Vlasveld LT
Acta Haematol; 2012; 128(3):183-6. PubMed ID: 22890406
[TBL] [Abstract][Full Text] [Related]
40. Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases.
Horn T; Kremer M; Dechow T; Pfeifer WM; Geist B; Perker M; Duyster J; Quintanilla-Martinez L; Fend F
J Mol Diagn; 2006 Jul; 8(3):299-304. PubMed ID: 16825501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]